Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, vaccines and immunoinformatics approaches, Cancer Immunotherapy and Biomarkers, and CAR-T cell therapy research.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
MC38 colorectal tumor cell lines from two different sources display substantial differences in transcriptome, mutanome and neoantigen expression
CoVigator—A Knowledge Base for Navigating SARS-CoV-2 Genomic Variants
Identification of neoantigens for individualized therapeutic cancer vaccines
Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens
Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates
NeoFox: annotating neoantigen candidates with neoantigen features
A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model
Bioinformatics for Cancer Immunotherapy
Integrative analysis of structural variations using short-reads and linked-reads yields highly specific and sensitive predictions
A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening
HLA and proteasome expression body map
Challenges towards the realization of individualized cancer vaccines
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
Abstract A110: Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination
Tick Salivary Sialostatin L Represses the Initiation of Immune Responses by Targeting IRF4-Dependent Transcription in Murine Mast Cells
In Silico HLA Typing Using Standard RNA-Seq Sequence Reads
Abstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer